Montila LC Tablet is a fixed-dose combination medication containing 5mg of levocetirizine and 10mg of montelukast, indicated for the treatment of chronic idiopathic urticaria (CIU) and allergic rhinitis. Levocetirizine, an antihistamine, provides rapid relief from pruritus and hives, while montelukast, a leukotriene receptor antagonist, offers sustained bronchodilation and anti-inflammatory effects. This combination therapy aims to provide comprehensive symptom management for patients with chronic allergic conditions. The tablet is designed for once-daily administration, allowing for consistent dosing and improved patient compliance. In clinical trials, Montila LC Tablet demonstrated efficacy in reducing pruritus, hives, and nasal symptoms, as well as improving quality of life. The most common adverse reactions reported include headache, diarrhea, and nasopharyngitis. Caution should be exercised in patients with liver impairment, and concomitant use with other medications may require dose adjustments. As with all medications, patient tolerance and response may vary, and further evaluation is necessary to determine optimal dosing and duration of treatment.